Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.40 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2886687 | 0.88 | KMT2A (0.57) | MEN1KMT2APABPC1HPGDSMN1; SMN2 | |
| SCHEMBL4011814 | 0.85 | MEN1 (0.54) | MEN1KMT2APABPC1HPGDL3MBTL1 | |
| SCHEMBL13027973 | 0.85 | MEN1 (0.51) | MEN1KMT2APABPC1HPGDSMN1; SMN2 | |
| SCHEMBL2885903 | 0.84 | MEN1 (0.50) | MEN1KMT2APABPC1HPGDPKM | |
| SCHEMBL2889516 | 0.83 | MEN1 (0.52) | MEN1KMT2APABPC1HPGDSMN1; SMN2 | |
| SCHEMBL13799945 | 0.83 | MEN1 (0.55) | MEN1KMT2APABPC1HPGDSMN1; SMN2 | |
| SCHEMBL25435017 | 0.83 | KMT2A (0.54) | MEN1KMT2APABPC1HPGDSMN1; SMN2 | |
| SCHEMBL13027994 | 0.83 | MEN1 (0.63) | MEN1KMT2APABPC1SMN1; SMN2CA12 | |
| SCHEMBL2889998 | 0.83 | MEN1 (0.63) | MEN1KMT2APABPC1HPGDMAPK1 | |
| SCHEMBL13027731 | 0.83 | MEN1 (0.71) | MEN1KMT2APABPC1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100143340-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | SCHERING CORPORATION | 2010-06-10 | — | — | US | claimed |
| EP-2121018-A2 | TREATING CANCER WITH ANTI-IGF1R ANTIBODY 19D12=SCH 717454 | SCHERING CORPORATION (US) | 2009-11-25 | — | — | EP | claimed |
| WO-2008076257-A2 | TREATING CANCER WITH ANTI-IGFLR ANTIBODY 19D12 = SCH 717454 | SCHERING CORPORATION (US) | 2008-06-26 | — | — | WO | claimed |
| US-5260291-A | Tetrazine derivatives | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-11-09 | — | — | US | claimed |
| EP-3116507-B1 | COMPOUNDS FOR ORAL TREATMENT OF BRAIN TUMORS | KADMON CORP LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10080752-B2 | Treatment of brain and central nervous system tumors | KADMON CORPORATION, LLC (US) | 2018-09-25 | — | — | US | disclosed |
| US-20170071943-A1 | TREATMENT OF BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS | KADMON CORPORATION, LLC | 2017-03-16 | — | — | US | disclosed |
| EP-3116507-A1 | TREATMENT OF BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS | Kadmon Corporation, LLC (US) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015138420-A1 | TREATMENT OF BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS | KADMON CORPORATION, LLC (US) | 2015-09-17 | — | — | WO | disclosed |
| US-8450479-B2 | 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use | PHARMINOX LIMITED (GB) | 2013-05-28 | — | — | US | disclosed |
| US-8450479-B2 | 3-substituted-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5-tetrazine-8-carboxylic acid amides and their use | PHARMINOX LIMITED (GB) | 2013-05-28 | — | — | US | disclosed |
| US-20130012706-A1 | Methods and Intermediates for the Synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines | PHARMINOX LIMITED (GB) | 2013-01-10 | — | — | US | disclosed |
| WO-2009077741-A2 | 3-SUBSTITUTED-4-OXO-3,4-DIHYDRO-IMIDAZO-[5,1-D][1,2,3,5-TETRAZINE-8-CARBOXYLIC ACID AMIDES AND THEIR USE | PHARMINOX LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
| WO-2008076257-A2 | TREATING CANCER WITH ANTI-IGFLR ANTIBODY 19D12 = SCH 717454 | SCHERING CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1896505-A2 | ANTI-IGF1R ANTIBODY FORMULATIONS | SCHERING CORPORATION (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006138315-A2 | ANTI-IGF1R ANTIBODY FORMULATIONS | SCHERING CORPORATION (US) | 2006-12-28 | — | — | WO | disclosed |
| US-20060286103-A1 | Stable antibody formulation | MERCK SHARP & DOHME CORP. | 2006-12-21 | — | — | US | disclosed |
| US-20060205810-A1 | Platinum therapeutic combinations | SCHERING CORPORATION | 2006-09-14 | — | — | US | disclosed |
| WO-2006057998-A1 | BINARY ANTITUMOR COMPOSITIONS PLATINUM (IV) DERIVATIVES | SCHERING CORPORATION (US) | 2006-06-01 | — | — | WO | disclosed |
| US-5260291-A | Tetrazine derivatives | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1993-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071943-A1 | TREATMENT OF BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS | ERBB2, EGFR, ERBB3 | MEN1 2161/4885KMT2A 315/4885PABPC1 4868/4885 |
| US-10080752-B2 | Treatment of brain and central nervous system tumors | ERBB2, EGFR, ERBB3 | MEN1 2161/4885KMT2A 315/4885PABPC1 4868/4885 |
| US-20130012706-A1 | Methods and Intermediates for the Synthesis of 4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazines | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA6, TALDO1 | MEN1 216/4885KMT2A 327/4885PABPC1 4575/4885 |
| US-20100143340-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, KLK3, CD44 | MEN1 766/4885KMT2A 2490/4885PABPC1 916/4885 |
| US-20060205810-A1 | Platinum therapeutic combinations | MGMT, PARP2, TYMP | MEN1 402/4885KMT2A 1057/4885PABPC1 736/4885 |
| US-20060286103-A1 | Stable antibody formulation | FCGR3B, FCGR2A, FCGR1A | MEN1 1331/4885KMT2A 2046/4885PABPC1 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.